{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:13:46Z","timestamp":1788437626734,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jocn.2026.111877","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:30:57Z","timestamp":1769628657000},"page":"111877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Longitudinal effects of dimethyl fumarate on patient-reported outcome measures in multiple sclerosis: treatment satisfaction, quality of life, depressive symptoms, sleep, and work productivity"],"prefix":"10.1016","volume":"146","author":[{"given":"Roya","family":"Abolfazli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Shaygannejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereshteh","family":"Ashtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareh","family":"Shahmohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Poursadeghfard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohammad","family":"Baghbanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastaran","family":"Majdinasab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Nahayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaneh","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad Yousefi","family":"Azarfam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Navardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza","family":"Torabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hormoz","family":"Ayromlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Saeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Talebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Nikseresht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Niknam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirreza","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnaz","family":"Sedighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Ghiasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Ghalyanchi-Langroodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Pourakbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hora","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Kamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Mohammadianinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Ghaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Mosarrezaii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asghar","family":"Bayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Yaseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Shali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Samadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2026.111877_b0005","doi-asserted-by":"crossref","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816-21.","DOI":"10.1177\/1352458520970841"},{"issue":"1","key":"10.1016\/j.jocn.2026.111877_b0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.jocn.2026.111877_b0015","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jocn.2026.111877_b0020","doi-asserted-by":"crossref","DOI":"10.1097\/WCO.0000000000000821","article-title":"Measuring outcomes that matter most to people with multiple sclerosis: the role of patient-reported outcomes","volume":"33","author":"Brichetto","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.jocn.2026.111877_b0025","article-title":"The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care \u2013 updates at the 2023 plenary event","volume":"15\u20132024","author":"Zaratin","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.jocn.2026.111877_b0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.msard.2019.05.019","article-title":"Review: patient-reported outcomes in multiple sclerosis care","volume":"33","author":"D'Amico","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jocn.2026.111877_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103757","article-title":"The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: progresses and open questions","volume":"61","author":"Zaratin","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.jocn.2026.111877_b0040","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s13311-017-0571-6","article-title":"Evolution of patient-reported outcomes and their role in multiple sclerosis clinical trials","volume":"14","author":"Nowinski","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.jocn.2026.111877_b0045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"10.1016\/j.jocn.2026.111877_b0050","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/1352458516657441","article-title":"Measuring treatment satisfaction in MS: is the treatment satisfaction questionnaire for medication fit for purpose?","volume":"23","author":"Vermersch","year":"2017","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.jocn.2026.111877_b0055","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1191\/1352458503ms902oa","article-title":"Validity of the beck depression inventory-fast screen in multiple sclerosis","volume":"9","author":"Benedict","year":"2003","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.jocn.2026.111877_b0060","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0005-7967(97)00025-9","article-title":"Screening for major depression disorders in medical inpatients with the beck depression inventory for primary care","volume":"35","author":"Beck","year":"1997","journal-title":"Behav Res Ther"},{"issue":"7","key":"10.1016\/j.jocn.2026.111877_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11072037","article-title":"Psychometric properties of the pittsburgh sleep quality index (PSQI) in patients with multiple sclerosis: factor structure, reliability, correlates, and discrimination","volume":"11","author":"Jerkovi\u0107","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.jocn.2026.111877_b0070","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The pittsburgh sleep quality index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res"},{"issue":"5","key":"10.1016\/j.jocn.2026.111877_b0075","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jocn.2026.111877_b0080","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/1352458513507817","article-title":"Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study","volume":"20","author":"Kappos","year":"2014","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.jocn.2026.111877_b0085","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1352458513507818","article-title":"Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study","volume":"20","author":"Kita","year":"2014","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.jocn.2026.111877_b0090","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jocn.2026.111877_b0095","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jocn.2026.111877_b0100","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.clinthera.2017.06.012","article-title":"Efficacy and safety of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis in prior interferon users: an integrated analysis of DEFINE and CONFIRM","volume":"39","author":"Fern\u00e1ndez","year":"2017","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.jocn.2026.111877_b0105","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40120-023-00475-8","article-title":"Efficacy of dimethyl fumarate in young adults with relapsing-remitting multiple sclerosis: analysis of the DEFINE, CONFIRM, and ENDORSE studies","volume":"12","author":"Amezcua","year":"2023","journal-title":"Neurol Ther"},{"issue":"5","key":"10.1016\/j.jocn.2026.111877_b0110","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/13524585211037909","article-title":"Long-term safety and efficacy of dimethyl fumarate for up to 13\u2009years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results","volume":"28","author":"Gold","year":"2022","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.jocn.2026.111877_b0115","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.clinthera.2014.08.013","article-title":"Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies","volume":"36","author":"Kita","year":"2014","journal-title":"Clin Ther"},{"issue":"12","key":"10.1016\/j.jocn.2026.111877_b0120","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.clinthera.2018.10.011","article-title":"effectiveness of delayed-release dimethyl fumarate on clinical and patient-reported outcomes in patients with relapsing multiple sclerosis switching from glatiramer acetate: RESPOND, a prospective observational study","volume":"40","author":"Kresa-Reahl","year":"2018","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.jocn.2026.111877_b0125","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40120-020-00223-2","article-title":"Effectiveness of dimethyl fumarate in patients with relapsing multiple sclerosis switching after suboptimal response to glatiramer acetate, including patients with early multiple sclerosis: subgroup analysis of RESPOND","volume":"10","author":"Repovic","year":"2021","journal-title":"Neurol Ther"},{"issue":"4","key":"10.1016\/j.jocn.2026.111877_b0130","article-title":"Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC","volume":"5","author":"Berger","year":"2019","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"2","key":"10.1016\/j.jocn.2026.111877_b0135","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40120-020-00193-5","article-title":"Real-world safety and effectiveness of dimethyl fumarate in black or african american patients with multiple sclerosis: 3-year results from ESTEEM","volume":"9","author":"Williams","year":"2020","journal-title":"Neurol Ther"},{"issue":"1","key":"10.1016\/j.jocn.2026.111877_b0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40120-016-0061-5","article-title":"Quantifying the benefits of dimethyl fumarate over \u03b2 interferon and glatiramer acetate therapies on work productivity outcomes in MS patients","volume":"6","author":"Lee","year":"2017","journal-title":"Neurol Ther"},{"key":"10.1016\/j.jocn.2026.111877_b0145","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.2147\/PPA.S187529","article-title":"Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence","volume":"13","author":"Narapureddy","year":"2019","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.jocn.2026.111877_b0150","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40120-024-00680-z","article-title":"Long-term safety and effectiveness of dimethyl fumarate in patients with multiple sclerosis treated in routine medical practice: final analysis of the ESTEEM study","volume":"14","author":"Pandey","year":"2025","journal-title":"Neurol Ther"},{"key":"10.1016\/j.jocn.2026.111877_b0155","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2147\/PROM.S168095","article-title":"Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: patient reported outcomes and perspectives","volume":"10","author":"Ozel","year":"2019","journal-title":"Patient Relat Outcome Meas"},{"issue":"2","key":"10.1016\/j.jocn.2026.111877_b0160","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.jocn.2026.111877_b0165","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12955-020-01365-5","article-title":"Health-related quality of life measured using the EQ-5D\u20135\u2009L: population norms for the capital of Iran","volume":"18","author":"Emrani","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jocn.2026.111877_b0170","doi-asserted-by":"crossref","unstructured":"EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"10.1016\/j.jocn.2026.111877_b0175","article-title":"Psychometric properties of the persian version of the short beck depression inventory with iranian psychiatric outpatients","volume":"2016","author":"Dadfar","year":"2016","journal-title":"Scientifica (Cairo)"},{"issue":"7","key":"10.1016\/j.jocn.2026.111877_b0180","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/17476348.2020.1750373","article-title":"Validation of the Persian work productivity and activity impairment questionnaire in asthmatic patients","volume":"14","author":"Seyedrezazadeh","year":"2020","journal-title":"Expert Rev Respir Med"},{"issue":"20","key":"10.1016\/j.jocn.2026.111877_b0185","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"Association","year":"2013","journal-title":"J Am Med Assoc"},{"issue":"s01","key":"10.1016\/j.jocn.2026.111877_b0190","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.33588\/rn.76S01.2022296","article-title":"Actual adherence to dimethyl fumarate in patients with relapsing-remitting multiple sclerosis","volume":"76","author":"de S\u00e1","year":"2023","journal-title":"Rev Neurol"},{"key":"10.1016\/j.jocn.2026.111877_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104080","article-title":"Adherence and discontinuation rates in patients on Tecfidera\u2122 (dimethyl fumarate): long-term canadian experience from the biogen ONE\u2122 support program","volume":"67","author":"Thompson","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jocn.2026.111877_b0200","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.msard.2018.05.007","article-title":"Real-life persistence and tolerability with dimethyl fumarate","volume":"24","author":"Sejbaek","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"10.1016\/j.jocn.2026.111877_b0205","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1007\/s00415-020-09848-7","article-title":"Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life spanish population","volume":"267","author":"Sabin","year":"2020","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.jocn.2026.111877_b0210","first-page":"963","article-title":"Safety and efficacy of dimethyl fumarate in multiple sclerosis: an Italian, multicenter","volume":"32","author":"Mirabella","year":"2018","journal-title":"Real-World Study CNS Drugs"},{"issue":"8","key":"10.1016\/j.jocn.2026.111877_b0215","first-page":"844","article-title":"Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year","volume":"23","author":"Johnson","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jocn.2026.111877_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105127","article-title":"Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study","volume":"80","author":"Roar","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.jocn.2026.111877_b0225","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00415-018-9144-9","article-title":"Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience","volume":"266","author":"D'Amico","year":"2019","journal-title":"J Neurol"},{"issue":"18","key":"10.1016\/j.jocn.2026.111877_b0230","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s40265-019-01229-3","article-title":"Dimethyl fumarate: a review in relapsing-remitting MS","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.jocn.2026.111877_b0235","first-page":"1394","article-title":"Adherence to disease-modifying therapies for multiple sclerosis","volume":"22","author":"Higuera","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.jocn.2026.111877_b0240","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s13104-016-2243-8","article-title":"The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis","volume":"9","author":"Wicks","year":"2016","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jocn.2026.111877_b0245","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1477-7525-12-66","article-title":"Estimating a minimal clinically important difference for the EuroQol 5-Dimension health status index in persons with multiple sclerosis","volume":"12","author":"Kohn","year":"2014","journal-title":"HealthQual Life Outcomes"},{"key":"10.1016\/j.jocn.2026.111877_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111487","article-title":"Systematic review reveals that EQ-5D minimally important differences vary with treatment type and may decrease with increasing baseline score","volume":"174","author":"Cheng","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jocn.2026.111877_b0255","doi-asserted-by":"crossref","DOI":"10.4103\/aam.aam_259_24","article-title":"Evaluating the impact of teriflunomide and dimethyl fumarate on quality of life in relapsing-remitting multiple sclerosis: insights from eastern Saudi Arabia","author":"Alshayban","year":"2025","journal-title":"Ann Afr Med"},{"issue":"1","key":"10.1016\/j.jocn.2026.111877_b0260","article-title":"Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: a multicentre Italian wearable tracker study","volume":"9","author":"Comi","year":"2023","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"1","key":"10.1016\/j.jocn.2026.111877_b0265","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12874-024-02297-0","article-title":"The gap between statistical and clinical significance: time to pay attention to clinical relevance in patient-reported outcome measures of insomnia","volume":"24","author":"Qin","year":"2024","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.jocn.2026.111877_b0270","article-title":"Minimally important difference for WPAI:CD scores: defining relevant impact on work productivity in active crohn's disease: 962","volume":"102","author":"Sandborn","year":"2007","journal-title":"Off J Am Coll Gastroenterol"},{"issue":"1","key":"10.1016\/j.jocn.2026.111877_b0275","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s41687-018-0088-8","article-title":"Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review","volume":"2","author":"Yarlas","year":"2018","journal-title":"J Patient Rep Outcomes"},{"issue":"5","key":"10.1016\/j.jocn.2026.111877_b0280","doi-asserted-by":"crossref","first-page":"236","DOI":"10.7224\/1537-2073.2014-069","article-title":"Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate","volume":"17","author":"Phillips","year":"2015","journal-title":"Int J MS Care"},{"issue":"1","key":"10.1016\/j.jocn.2026.111877_b0285","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s12325-024-03047-w","article-title":"Real-world safety and effectiveness of dimethyl fumarate in patients with MS: results from the ESTEEM phase 4 and PROCLAIM phase 3 studies with a focus on older patients","volume":"42","author":"Mao-Draayer","year":"2025","journal-title":"Adv Ther"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586826000287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586826000287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:55:59Z","timestamp":1770645359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586826000287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":57,"alternative-id":["S0967586826000287"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2026.111877","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal effects of dimethyl fumarate on patient-reported outcome measures in multiple sclerosis: treatment satisfaction, quality of life, depressive symptoms, sleep, and work productivity","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2026.111877","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111877"}}